Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-021"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"sv"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-021"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0222
lpv:speaker	lp:Astrid Thors2
lpv:spokenAs	substitute; Committee on Legal Affairs and the Internal Market (2002-01-17--2004-07-19)3 unknown; Svenska folkpartiet (1999-07-20--2004-07-19)3 vice-chair; PETI (2002-01-23--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3 substitute; Delegation to the European Economic Area Joint Parliamentary Committee (EEA) (2002-02-07--2004-07-19)3 member; Delegation to the EU-Latvia Joint Parliamentary Committee (2002-02-07--2004-04-30)3 member_of_the_bureau; ELDR (1999-07-20--2004-07-19)3
lpv:translated text	"Commissioner and rapporteurs, I would like to thank our rapporteurs for their excellent work on a quite impenetrable matter. I normally do not thank the rapporteurs, but there is good reason to do so in this case, as it is extremely difficult to attempt to master the whole of this large area. Ladies and gentlemen, we all know that the costs of medicines in many EU countries constitute the fastest growing element of healthcare costs. In many countries, the shortfall in funding specifically for medicines is quite large. I therefore believe it was important that the Health Ministers were involved in this issue before the Council was restructured to increase efficiency. I hope that the Health Ministers will also be involved in the future. I usually also remain highly sceptical when Parliament asks the Commission for more reports. This time, I believe, however, that it would be important for the Commission to follow up trends in medicine prices, taking into account differences in different countries. This may provide us with very valuable information on various restrictions. I support what my colleague Mr Maaten said on access to information and what the Commissioner said regarding the fact that the issue is not advertising but access to information. We have many examples of information and other support being given to doctors in an unacceptable manner. Monitoring information would allow us to keep better track of how much money is being used in this sector. I see this as important. I believe one of the major problems, which many of the amendments also seize upon, is that we have what has been referred to as paid research. Many respected newspapers have also given their pages over to this. Finally, I, like Mr Rod, stress that I am glad that the effect of medicines on the environment will also be taken into account. It is not that we wish to set up obstacles to medicines but that the positive effects must be evaluated in relation to other effects."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph